NASDAQ:ADGM

Adagio Medical Q1 2026 Earnings Results & Report

Adagio Medical logo
$1.75 +0.09 (+5.42%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.75 +0.00 (+0.11%)
As of 11/20/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adagio Medical missed analyst earnings expectations in its Q1 2026 results, released May 12, 2026. The company reported EPS of -$9.30 versus the -$8.70 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Adagio Medical EPS Results

Actual EPS
-$9.30
Consensus EPS
-$8.70
Beat/Miss
Missed by -$0.60
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Adagio Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adagio Medical Q1 2026 Earnings FAQ

Adagio Medical (NASDAQ:ADGM) reported earnings of -$9.30 per share for Q1 2026, missing the consensus estimate of -$8.70. The report was announced on Tuesday, May 12, 2026.

Adagio Medical Earnings Headlines

Adagio Medical Reports Third Quarter 2026 Results
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Adagio Medical (ADGM) Expected to Post Earnings on Wednesday
ADGM - Adagio Medical Holdings, Inc.
See More Adagio Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adagio Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagio Medical and other key companies, straight to your email.

About Adagio Medical

Adagio Medical (NASDAQ:ADGM) is a medical technology company developing catheter-based systems for treating cardiac arrhythmias. Its technology uses ultra-low-temperature cryoablation, which applies very cold temperatures to create lesions in heart tissue that can interrupt abnormal electrical signals.

The company’s platform includes the vCLAS system, designed for ventricular arrhythmias such as ventricular tachycardia, and the iCLAS system, designed for atrial fibrillation. These systems are intended for use in catheter ablation procedures by cardiac electrophysiology teams.

View Adagio Medical Profile